 |
ESO INSIDE TRACK CONFERENCE
Chair: J.Benitez, ES - R. Eeles, UK - H.Vasen, NL
ABSTRACT SUBMISSION
Poster abstract deadline 1 APRIL 2008.
You may submit your abstract to the Organising Secretariat online at: WWW.CNIO.ES/MEETINGS
Instructions for abstract submission
Participants with new data relevant to the subject of the conference may submit one abstract to
be considered for poster presentation. Only papers whose abstracts have been reviewed and
approved by the conference co-ordinator will be presented.
Abstracts should be written in English and the text should not exceed 2000 characters (or 450
words), title included.
The title should appear in capital letters.
For each author, type surname first, followed by first name and initials (presenting author in
capital letters).
List affiliations after the author's list.
Indicate 3-5 keywords at the end of the text.
The full address with telephone, fax number and email of the corresponding author must be
provided. This author will receive all the subsequent communication concerning this abstract.
Please also indicate your approval for publication in case the abstracts are issued in a journal.
Please note: Only abstracts submitted by registered participants will be accepted. Please do not
forget to mark on the registration form that you have submitted an abstract.
6 posters will be selected for the oral presentation that will take place on the 5 June.
It is the responsibility of the presenting author to ascertain whether all authors are aware of the
content of the abstract before submission.
FACULTY
L. Aaltonen, University of Helsinki, FI
J. Balmaña, Hospital Universitari Vall d'Hebron, Barcelona, ES
L. Bancroft, Royal Marsden NHS Foundation Trust, Sutton, UK
J. Benitez, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
I. Blanco, Instituto Catalán de Oncología, Barcelona, ES
D. Eccles, Southampton University Hospital Trust, Southampton, UK
R. Eeles, Inst. for Cancer Research and The Royal Marsden NHS Trust, Sutton, UK
T. Frebourg, Rouen University Hospital, Rouen, FR
D. Goldgar, University of Utah, Salt Lake City, US
K. Hemminki, Deutsches Krebsforschungszentrum, Heidelberg, DE
C. Houdayer, Institut Curie, Paris, FR
P. Lapunzina, Hospital La Paz, Madrid, ES
C. Lazaro, Institut Català d'Oncologia, Barcelona, ES
M. Longy, Institut Bergonié, Bordeaux Cedex, FR
B. Martinez-Delgado, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
H.P.H. Neumann, Albert-Ludwigs-University, Freiburg, DE
H. Nevanlinna, Joint Authority for the Hospital District of Helsinki and Uusimaa, Helsinki, FI
P. Nicolas, Universidad de Deusto, Bilbao, ES
A. Osorio, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
J. Palacios, Hospitales Universitarios Virgen del Rocio, Sevilla, ES
N. Rahman, The Institute of Cancer Research: Royal Cancer Hospital, London, UK
M. Robledo, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
J. Suralles, Universitat Autonoma de Barcelona, ES
S. Tavtignan, International Agency for Research on Cancer, Lyon Cedex, FR
M. Urioste, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
L. Valle, The Ohio State University, Columbus, US
H. Vasen, Leiden University Medical Centre, Leiden, NL
Further information
|
|
